<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36728467</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-0237</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of thoracic imaging</Title><ISOAbbreviation>J Thorac Imaging</ISOAbbreviation></Journal><ArticleTitle>Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>W30</StartPage><EndPage>W32</EndPage><MedlinePgn>W30-W32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/RTI.0000000000000694</ELocationID><Abstract><AbstractText>Antimalarial-induced cardiomyopathy is under-recognized in clinical practice and there is limited data on the evolution of cardiac imaging abnormalities after cessation of anti-malarial therapy. In this case series of 9 patients with antimalarial-induced cardiomyopathy, follow-up cardiac magnetic resonance imaging demonstrated interval increase in late gadolinium enhancement extent in 89% of patients and interval decrease in left ventricular ejection fraction in all, despite cessation of anti-malarial therapy. Progression of cardiac abnormalities despite cessation of therapy underscores the important role of imaging in the early recognition of antimalarial-related treatment changes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shalmon</LastName><ForeName>Tamar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Joint Department of Medical Imaging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thavendiranathan</LastName><ForeName>Paaladinesh</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Joint Department of Medical Imaging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, University of Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Women's College Hospital, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akhtari</LastName><ForeName>Shadi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Women's College Hospital, University of Toronto, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tselios</LastName><ForeName>Kostantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, University of Toronto Lupus Clinic, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladman</LastName><ForeName>Dafna D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, University of Toronto Lupus Clinic, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanneman</LastName><ForeName>Kate</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3077-2218</Identifier><AffiliationInfo><Affiliation>Joint Department of Medical Imaging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, University of Toronto.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Imaging</MedlineTA><NlmUniqueID>8606160</NlmUniqueID><ISSNLinking>0883-5993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>AU0V1LM3JT</RegistryNumber><NameOfSubstance UI="D005682">Gadolinium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="Y">Antimalarials</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019028" MajorTopicYN="N">Magnetic Resonance Imaging, Cine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005682" MajorTopicYN="N">Gadolinium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>K.H. has received a speaker&#x2019;s honorarium from Sanofi-Genzyme, Amicus, and Medscape. P.T. has received speaker&#x2019;s honorarium from Amgen, BI, and Takeda. The remaining authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36728467</ArticleId><ArticleId IdType="doi">10.1097/RTI.0000000000000694</ArticleId><ArticleId IdType="pii">00005382-202305000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tselios K, Deeb M, Gladman DD, et al. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018;27:591&#x2013;599.</Citation></Reference><Reference><Citation>Hanneman K, Alberdi HV, Karur GR, et al. Antimalarial-induced cardiomyopathy resembles fabry disease on cardiac MRI. JACC Cardiovasc Imaging. 2020;13:879&#x2013;881.</Citation></Reference><Reference><Citation>Michaelides M, Stover NB, Francis PJ, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129:30&#x2013;39.</Citation></Reference><Reference><Citation>Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet. 1993;25:392&#x2013;407.</Citation></Reference><Reference><Citation>Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med. 1983;75:5&#x2013;10.</Citation></Reference><Reference><Citation>Frustaci A, Morgante E, Antuzzi D, et al. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. Int J Cardiol. 2012;157:117&#x2013;9.</Citation></Reference><Reference><Citation>Hanneman K, Karur GR, Wasim S, et al. Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in fabry disease. Radiology. 2020;294:42&#x2013;49.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>